DONATE TODAY
To Increase Patient Access
End Brain Cancer Mobile App to download your number one tool for navigating this disease.

May 7, 2022

ADVANCED MRI APPLICATIONS FOR RECURRENT GLIOBLASTOMA BRAIN TUMORS & A NEW PHASE 1 CLINICAL TRIAL

Imaging Biometrics (IB), www.imagingbiometrics.com, has been developing imaging analysis software for primary brain tumors for close to 30 years. They are moving the frontier for improved diagnosis and treatment monitoring. Recently, Imaging Biometrics imaging software was used to assess treatment response in a pre-clinical study conducted at the Medical College of Wisconsin. The pre-clinical results demonstrated that an oral agent (Gallium Maltolate) successfully shrunk glioma tumors and significantly extended overall survival. In one case, the tumor completely disappeared. To IB’s knowledge, prior use of Gallium Maltolate has caused no adverse side effects in patients and studies have shown the agent can successfully cross the blood-brain-barrier and access the tumor site. A Phase I trial started on March 11,2022.

Imaging Biometrics is excited to announce a Phase I clinical trial to assess the safety and preliminary efficacy of oral gallium maltolate (GaM) in participants with relapsed glioblastoma (GBM). The study will take place at the Medical College of Wisconsin under the direction of Dr. Jennifer Connelly. For more information, go to www.Clinicaltrials.gov and locate study identifier #: NCT04319276 or contact the Cancer Center Clinical Trials Office, 866-680-0505 ext. 8900, ccto@mcw.edu.

The study is an investigator-initiated trial (IIT) based on extensive preclinical research conducted on the antineoplastic activity of gallium compounds. Gallium Maltolate is a second generation oral agent, with improved GI absorption and crosses the blood brain barrier.

IB’s Clinic suite of products are renowned for dramatically improving the ability of hospitals, clinics, and research organizations to get the most out of their magnetic resonance (MR) and computed tomography (CT) data. This improves the medical professional’s ability to diagnosis and treat patients. Conventional imaging is not capable of answering critical questions, specifically, is the enhancing region tumor or is it an effect due to treatment? Thus, IB software offers several distinct advantages to patients. IB software is repeatedly influencing the treatment and surgical decisions for glioblastoma patients and their care teams!

Photo of Dellann

Dellann Elliott Mydland
President & Board Chair

The EndBrainCancer Initiative | Chris Elliott Fund
Dellann@EndBrainCancer.org

EndBrainCancer.org

ENDBRAINCANCER INITIATIVE | CHRIS ELLIOTT FUND

Enhancing patient outcomes by expanding FDA-approved treatment modalities and fueling research in the pharma/bio/life sciences, device & diagnostic industries and by closing the existing GAP from initial diagnosis to IMMEDIATE AND EXPANDED ACCESS to specialists, researchers, advanced & innovative treatments, clinical trials and critical care with the ultimate goal of improving patient outcomes through updating and improving WHO & NCCN Guidelines and clinical practices related to Standard of Care for brain cancer patients.

TAX ID:26-2185614
DONATE
corporate partners
upcoming events
resources
About us
envelopephonemap-markerpointer-right
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram